// App-Quantinova.ai

688 : Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network

Researchers

Presenter

  • Pieter Sonneveld

Principal Investigators

  • Emilie Asselberg-Hacker

  • Sonja Zweegman

  • Bronno van der Holt

  • Marie Jose Kersten

  • Edo Vellenga

  • Marinus van Marwijk Kooy

  • Okke de Weerdt

  • Sarah Lonergan

  • Antonio Palumbo

  • Henk M. Lokhorst

Medical Centers

  • Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands

  • Department of Internal Medicine, Isala Clinic, Zwolle, Netherlands

  • Hematology, Erasmus Medical Center-Daniel den Hoed Cancer Center, Rotterdam, Netherlands

  • Hematology, Erasmus Medical Center, Rotterdam, Netherlands

  • Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, Netherlands

  • Erasmus MC, Rotterdam, Netherlands

  • Department of Hematology, University Hospital Groningen, Groningen, Netherlands

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • hematology, amc, amsterdam, Netherlands

  • HOVON Data Centre Erasmus MC-Daniel den Hoed, Rotterdam, Netherlands

  • University of Torino, Azienda Ospedaliero-Universitaria AOU S. Giovanni Battista Torino, Torino, Italy

Locations

  • Italy

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Renal insufficiency

Biomarkers

  • Circulating tumor cells

  • Cluster of Differentiation 34

  • Creatinine

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

  • Thalidomide

  • Melphalan

  • Filgrastim

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved